Oral mucositis is one of the most common side effects cancer patients experience when undergoing chemotherapy. However, it is frequently under-reported and leads to high morbidity and complication rates. Advances in molecular biology have provided greater insight into the pathophysiology of this condition. Although there are no current treatments that completely resolve this painful condition, encouraging research developments indicate that a new, over-the-counter pH-balanced salt solution, reBalance Ca , shows promise.
incidence rate of oral mucositis may be as high as 90%. 4 Patients receiving chemotherapy treatments using certain drugs such as 5-fluorouracil (5-FU) 5 and melphalan 6 have a higher incidence of oral mucositis than those receving other chemotherapy drugs. In general, the incidence rate of oral mucositis in cancer patients undergoing chemotherapy at standard doses is 40-60%. 7 Oral mucositis in patients undergoing chemotherapy treatments is frequently under-reported. 8 Patients often do not report oral mucositis if the symptoms are mild or if they are not queried about it.
Furthermore, the oral mucosa is not always examined by the medical care team. Oral mucositis in its early stages presents with erythema, mild pain, and mild dysphagia that is manageable with over-the-counter medications. Patients often make adjustments in their oral intake by decreasing intake of food and sometimes fluids as well.
When early-stage oral mucositis is identified, there are few effective treatments currently available. 9 Medications such as palifermin 10 and caphasol 11 are indicated for the prevention of oral mucositis in patients undergoing high-dose myeloablative therapies. They are, however, not indicated for the treatment of oral mucositis after chemotherapy has been administered.
In patients undergoing chemotherapy at standard doses, oral mucositis generally presents as grades 1 and 2 rather than grades 3 and 4. Even with these early grade presentations, patients will often not report it to their physicians or to their family members. 12 Patients can rapidly become dehydrated and malnourished and deteriorate to the severity of needing hospitalization. 13 Mucositis can lead to oral infections including viral, bacterial, and fungal infections. 14, 15 The ulceration of oral mucosa is a portal for these infections. If the patient is neutropenic from chemotherapy treatments, the local infection can become systemic.
Neutropenia enhances the degree of oral mucositis. The more serious the neutropenia, the more serious the oral mucositis. Patient quality of life can be affected by oral mucositis, and its consequences can result in treatment delays, hospitalizations, and unintended increases in medical costs. 8, 16 Treatment delays in particular can result in poorer outcomes for the patient.
There are no racial 17 or sexual predilections 18 to chemotherapy-induced oral mucositis. Younger patients tend to develop oral mucositis more often than older patients, possibly because of a more rapid turnover of basal cells in the oral mucosa of younger patients.
Recently, several studies [20] [21] [22] have shown that the complications caused by oral mucositis in cancer chemotherapy are very significant. These findings have created a broader understanding of oral mucositis and the need to treat it early in its presentation, rather than leaving it as an unmet medical need.
Chemotherapy Drugs Causing Oral Mucositis
Every chemotherapy drug can potentially cause oral mucositis. 23 Drug dose and schedule seem to be key in contributing to the incidence of oral mucositis. 23 Other important factors include the patient's general medical condition (performance status), comorbid conditions, and genetic predisposition (yet to be defined). 24, 25 Owing to the variability in the frequency of oral mucositis, the clinician should enquire about the symptoms of oral mucositis and inspect the mucosa frequently. Queries about oral pain and changes in nutritional status can be indicative of oral mucositis in the patient.
The use of biologic agents, especially in combination with chemotherapy, poses additional challenges. 26 The incidence of oral mucositis increases with the addition of biologic agents. There are other complications with biologic agents including allergic reactions, rashes, and other skin reactions.
Pathophysiology
Oral mucositis is a complex interaction of the epithelia and submucosa in response to chemotherapy administration. The interaction of these cells, mediated by reactive oxygen species (ROS), 27 can exacerbate the response, turning an area of erythema into an oral ulcer. Various transcription factors, especially nuclear factor kappa B (NFκB), 28 and a number of proinflammatory cytokines contribute to the amplification of signals, leading to tissue necrosis and ulcer formation. 
Consequences of Oral Mucositis
The consequences of oral mucositis can have serious implications for the patient. The morbidity of oral mucositis is reflected in the deterioration of quality of life. Table 1 shows the different grading scales for oral mucositis.
The ability of the patient to tolerate oral intake of liquids and solids remains crucial to the morbidity of oral mucositis. Strict attention to the nutritional abilities of the patient is critical to the patient's outcome.
Treatment Delays
Cancer 
Quality of Life
Oral mucositis has a major impact on a cancer patient's quality of life. 31 Being able to manage oral mucositis and all the consequences of its presentation, especially pain, infections, and malnutrition, is a challenge to clinicians.
Treatment of Oral Mucositis
Patients with oral mucositis can become extremely debilitated, and their quality of life greatly diminished. Unfortunately, there are only a few established treatments for oral mucositis, and their effectiveness is variable. Some of the most common treatments are detailed below.
Salt Rinses
Salt rinses have been advocated as being potentially helpful in treating oral ulcers and oral pain and improving dental health. Homemade salt solutions incorporating table salt and sometimes baking soda have been recommended by dentists to improve dental hygiene. Their benefit in treating oral mucositis, however, is anecdotal. 33 
Oral Debridement
Oral debridement can clear the oral mucosa of debris and devitalized tissues. With a soft toothbrush and/or sponge applicator, the oral mucosa, teeth, gums, and tongue can be brushed to debride overgrowth, clear dried saliva, and reduce pseudomembranes. Frequent rinsing with water will help wash away the debris and may improve oral health.
Prevention and Growth Factors
New understanding of the biologic process of oral mucositis has highlighted the potential of growth factors in preventing oral mucositis.
Several growth factors, including granulocyte colony-stimulating factor (G-CSF), 41 granulocyte-macrophage colony-stimulating factor (GM-CSF), [42] [43] [44] transforming growth factor-beta (TGF-β3), 45 and palifermin (recombinant human keratinocyte growth factor) are undergoing clinical studies in the prevention of oral mucositis.
Of these, palifermin 46, 47 has some potential in preventing the development of oral mucositis. It mediates epithelial cell growth and repair. It also decreases TNF-α, which is a proinflammatory mediator, and in the process facilitates mucosal healing. The action of the drug appears to be bi-modal, with a growth-enhancing differentiation and a cytoprotective effect throughout the GI tract.
In a double-blind, placebo-controlled study of palifermin, 10 212 patients with hematologic cancers were treated for three days before and three days after transplant. It was reported that there was a decrease in grade 3 and 4 oral mucositis, with 63% of palifermin-treated patients developing oral mucositis versus 98% of those in the placebo group (p<0.01). Additionally, there was a decrease in patient-reported 
Conclusion
Oral mucositis is a very serious complication of cancer chemotherapy. 
